Page 21 - 《中国药房》2021年23期

参考文献 [10] ZHANG H，LIN Y，LI K，et al. Naturally existing oncoly-
[ 1 ] SUNG H，FERLAY J，SIEGEL R L，et al. Global cancer tic virus M1 is nonpathogenic for the nonhuman primates
statistics 2020：GLOBOCAN estimates of incidence and after multiple rounds of repeated intravenous injec-
mortality worldwide for 36 cancers in 185 countries[J]. tions[J]. Hum Gene Ther，2016，27（9）：700-711.
CA Cancer J Clin，2021，71（3）：209-249. [11] LUNDSTROM K. Alphavirus vectors as tools in neuro-
[ 2 ] 周晖，白守民，林仲秋.《2019 NCCN 宫颈癌临床实践指 science and gene therapy[J]. Virus Res，2016，216：16-25.
南（第1版）》解读[J].中国实用妇科与产科杂志，2018，34 [12] HU H，TIAN M，DING C，et al. The C/EBP homologous
（9）：1002-1009. protein （CHOP） transcription factor functions in endo-
[ 3 ] SMALL W J R，BACON M A，BAJAJ A，et al. Cervical plasmic reticulum stress-induced apoptosis and microbial
cancer：a global health crisis [J]. Cancer，2017，123（13）： infection[J]. Front Immunol，2018，9：3083.
2404-2412. [13] LIN Y，ZHANG H，LIANG J，et al. Identification and
[ 4 ] LAWLER S E，SPERANZA M C，CHO C F，et al. Onco- characterization of alphavirus M1 as a selective oncolytic
lytic viruses in cancer treatment：a review[J]. JAMA Oncol， virus targeting ZAP-defective human cancers[J]. Proc
2017，3（6）：841-849. Natl Acad Sci U S A，2014，111（42）：E4504-E4512.
[ 5 ] RAJA J，LUDWIG J M，GETTINGER S N，et al. Onco- [14] CHUNG H C，ROS W，DELORD J P，et al. Efficacy and
lytic virus immunotherapy：future prospects for oncology safety of pembrolizumab in previously treated advanced
[J]. J Immunother Cancer，2018，6（1）：140. cervical cancer：results from the phase Ⅱ KEYNOTE-158
[ 6 ] CHESNEY J，PUZANOV I，COLLICHIO F，et al. Ran- study[J]. J Clin Oncol，2019，37（17）：1470-1478.
domized，open-label phase Ⅱ study evaluating the efficacy [15] HU C，LIU Y，LIN Y，et al. Intravenous injections of the
and safety of talimogene laherparepvec in combination oncolytic virus M1 as a novel therapy for muscle-invasive
with ipilimumab versus ipilimumab alone in patients with bladder cancer[J]. Cell Death Dis，2018，9（3）：274.
advanced，unresectable melanoma[J]. J Clin Oncol，2018， [16] ZHANG H，LI K，LIN Y，et al. Targeting VCP enhances
36（17）：1658-1667. anticancer activity of oncolytic virus M1 in hepatocellular
[ 7 ] 许青，陆舜，朱蕙燕，等.溶瘤病毒治疗恶性肿瘤临床应用 carcinoma[J]. Sci Transl Med，2017，9（404）：eaam7996.
上海专家共识：2021 年版[J].中国癌症杂志，2021，31 [17] WANG Y，HUANG H，ZOU H，et al. Liposome encapsula-
（3）：231-240. tion of oncolytic virus M1 to reduce immunogenicity and
[ 8 ] KESHAVARZ M，NEJAD A S M，ESGHAEI M，et al. On- immune clearance in vivo[J]. Mol Pharm，2019，16（2）：
colytic newcastle disease virus reduces growth of cervical 779-785.
cancer cell by inducing apoptosis[J]. Saudi J Biol Sci， [18] XIAO X，LIANG J，HUANG C，et al. DNA-PK inhibition
2020，27（1）：47-52. synergizes with oncolytic virus M1 by inhibiting antiviral
[ 9 ] KAGABU M，YOSHINO N，SAITO T，et al. The efficacy response and potentiating DNA damage[J]. Nat Commun，
of a third-generation oncolytic herpes simplex viral therapy 2018，9（1）：4342.
for an HPV-related uterine cervical cancer model[J]. Int J （收稿日期：2021-06-24 修回日期：2021-10-02）
Clin Oncol，2021，26（3）：591-597. （编辑：唐晓莲）

《中国药房》杂志——中文核心期刊，欢迎投稿、订阅

中国药房 2021年第32卷第23期 China Pharmacy 2021 Vol. 32 No. 23 ·2831 ·